Abstract
Background: The FDA-approved drugs for female sexual interest, desire and/or arousal disorder (FSIAD), and hypoactive sexual desire disorder (HSDD); however, these drugs have low tolerability for patients because of their multiple side effects and do not show actual therapeutic efficacy. Hypoactive Sexual Desire affects approximately 750.000.000 to 1.400.000.000 people worldwide.
Methods: In this paper, we analyze therapeutic candidates in clinical practice as well as the methodologies of clinicaltrials of possible therapeutic targets of different systems related to the disorder.
Results: Therefore, clinical trials of new drugs (benzodiazepines, amphetamines, testosterone, sildenafil, or new compound) to evaluate their efficacy in treating this disorder are necessary.
Keywords: Increases, sexual, interest, desire, arousal, new drugs, treatment.
Current Psychopharmacology
Title:Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder
Volume: 10
Author(s): Richard J. Wix*Ezequiel Uribe
Affiliation:
- Wixbiotech, CA, Naguanagua,Venezuela
Keywords: Increases, sexual, interest, desire, arousal, new drugs, treatment.
Abstract:
Background: The FDA-approved drugs for female sexual interest, desire and/or arousal disorder (FSIAD), and hypoactive sexual desire disorder (HSDD); however, these drugs have low tolerability for patients because of their multiple side effects and do not show actual therapeutic efficacy. Hypoactive Sexual Desire affects approximately 750.000.000 to 1.400.000.000 people worldwide.
Methods: In this paper, we analyze therapeutic candidates in clinical practice as well as the methodologies of clinicaltrials of possible therapeutic targets of different systems related to the disorder.
Results: Therefore, clinical trials of new drugs (benzodiazepines, amphetamines, testosterone, sildenafil, or new compound) to evaluate their efficacy in treating this disorder are necessary.
Export Options
About this article
Cite this article as:
Wix J. Richard *, Uribe Ezequiel , Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder, Current Psychopharmacology 2021; 10 (3) . https://dx.doi.org/10.2174/2211556010666210301144022
DOI https://dx.doi.org/10.2174/2211556010666210301144022 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans
Current Protein & Peptide Science DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Asymmetric Dimethyl-L-Arginine (ADMA): A Possible Link Between Homocyst(e)ine and Endothelial Dysfunction
Current Drug Metabolism Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Role of Cytochrome P450 Metabolites of Arachidonic Acid in Hypertension
Current Drug Metabolism Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Integrated Nutritional Supports for Diabetic Patients During COVID-19 Infection: A Comprehensive Review
Current Diabetes Reviews Editorial [(Poly)phenol Chemistry: Part II - Physicochemical Properties & Biological Implications (Guest Editor: Stefan Chassaing)]
Current Organic Chemistry Vitamin D-Binding Protein Acts in the Actin Scavenge System and Can Have Increased Expression During Aspirin Therapy
Current Neurovascular Research Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Epidemiology of Type 1 Diabetes in Latin America
Current Diabetes Reviews Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases
Current Drug Targets Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double –Edged Sword!
Recent Advances in Cardiovascular Drug Discovery (Discontinued)